Frank Hackl, MD
Interventional Pain Medicine · Tulsa, OKNPI 1912030404
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $554 and has fallen 72.1% since, to $154 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in OK, where the typical reported total is $5,016.
Across 93 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$222
- Scilex Pharmaceuticals Inc.$121
- Novartis$117
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
- Medtronic$103
- Assertio Therapeutics, Inc.$92
- plus $864 from 29 others
What the payments were for
- Food & beverage$1,633100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 14 | $222 |
| Scilex Pharmaceuticals Inc. | 7 | $121 |
| Novartis | 7 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $114 |
| Medtronic(2 entities) | 4 | $103 |
| Assertio Therapeutics, Inc. | 2 | $92 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Biodelivery Sciences International, Inc. | 4 | $67 |
| Pfizer | 4 | $65 |
| Abbott | 2 | $50 |
| GRT US Holding, Inc. | 3 | $47 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Nevro Corp. | 1 | $44 |
| AbbVie | 3 | $40 |
| Merck | 3 | $36 |
| Tersera Therapeutics LLC | 2 | $36 |
| Saluda Medical Americas, Inc. | 1 | $33 |
| Amgen | 2 | $30 |
| Eisai Inc. | 2 | $26 |
| Si-bone, Inc. | 1 | $25 |
| AstraZeneca | 2 | $25 |
| UCB, Inc. | 1 | $23 |
| Bioventus LLC | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sentynl Therapeutics, Inc. | 1 | $15 |
| Valinor Pharma, LLC | 1 | $15 |
| Orexo US, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Baudax Bio Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
How this compares
$1,633 in reported general payments places this provider in the 30th percentile of 27 interventional pain medicine providers in Oklahoma.
See all interventional pain medicine providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,204 | $133,866 |
| BelbucaBuprenorphine Hcl | 144 | $127,485 |
| RelistorMethylnaltrexone Bromide | 57 | $102,377 |
| Buprenorphine | 341 | $89,923 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,538 | $79,037 |
| MovantikNaloxegol Oxalate | 120 | $51,237 |
| OxycontinOxycodone Hcl | 105 | $43,659 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 197 | $42,492 |
| Xtampza ErOxycodone Myristate | 108 | $42,245 |
| ZtlidoLidocaine | 69 | $38,366 |
| Tramadol Hcl ErTramadol Hcl | 504 | $32,395 |
| Lidocaine | 236 | $30,378 |
| ButransBuprenorphine | 44 | $21,014 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 34 | $20,379 |
| Gabapentin | 1,593 | $19,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $222 | $176,183263 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $114 | $102,37757 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $121 | $38,36669 claims |
| Orexo US, Inc.Zubsolv | $15 | $20,37934 claims |
| AbbVieLinzess | $40 | $16,94931 claims |
| Eisai Inc.Dayvigo | $26 | $12,79440 claims |
| MerckBelsomra | $36 | $8,67720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 27 interventional pain medicine providers in Oklahoma.
Other interventional pain medicine in Tulsa
- Muhammad MaqboolTulsa$8K
- Samuel KorbeTulsa$7K
- Bhadresh BhaktaTulsa$1K
- Gerald HaleTulsa$1K
- Brandon ValantineOklahoma City$9K
- Amer NouhEdmond$8K
- Justin PorterOklahoma City$8K
- Joshua WoolardEdmond$7K
- Michael McLaughlinMoore$7K
- Steve RandallMidwest City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.